Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Mereo BioPharma (MREO) Profit After Tax (2023 - 2025)

Historic Profit After Tax for Mereo BioPharma (MREO) over the last 3 years, with Q3 2025 value amounting to -$7.0 million.

  • Mereo BioPharma's Profit After Tax rose 5317.65% to -$7.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$41.6 million, marking a year-over-year increase of 825.98%. This contributed to the annual value of -$43.3 million for FY2024, which is 4678.95% down from last year.
  • According to the latest figures from Q3 2025, Mereo BioPharma's Profit After Tax is -$7.0 million, which was up 5317.65% from -$14.6 million recorded in Q2 2025.
  • Mereo BioPharma's Profit After Tax's 5-year high stood at -$1.8 million during Q2 2023, with a 5-year trough of -$15.0 million in Q3 2024.
  • Moreover, its 3-year median value for Profit After Tax was -$9.1 million (2023), whereas its average is -$9.7 million.
  • As far as peak fluctuations go, Mereo BioPharma's Profit After Tax plummeted by 59988.58% in 2024, and later skyrocketed by 5317.65% in 2025.
  • Quarter analysis of 3 years shows Mereo BioPharma's Profit After Tax stood at -$9.1 million in 2023, then increased by 22.65% to -$7.0 million in 2024, then grew by 0.31% to -$7.0 million in 2025.
  • Its last three reported values are -$7.0 million in Q3 2025, -$14.6 million for Q2 2025, and -$12.9 million during Q1 2025.